For-Robin, Inc, founded in 2012 and named in honor of the founder’s sister who died at age 31 of breast cancer. For-Robin is preparing an IND for lung cancer imaging in collaboration with NCI NExT for 2023-2024 clinical imaging trials.
Our proprietary technology (monoclonal antibody, JAA-F11 and humanized variants, hJAA-F11) targets all breast and lung cancer cell subtypes including triple negative breast cancer where no targeted therapy currently exists. For-Robin is also developing hJAA-F11 for adjunct therapy of breast and lung cancer either directly or as antibody-drug conjugates.
Value has been added to For-Robin, Inc. through collaboration with the National Cancer Institute's NExT program. The NCI NExT program has performed 3rd party validation, facilitated the production of a cGMP stable cell line and production of cGMP antibody for clinical trials. Additionally, NCI NExt has facilitated the safety studies and interactions with the FDA.
The upcoming clinical trial will be with Dr. Grace Dy and other collaborators at Roswell Park Comprehensive Cancer Center.
President, Founder Dr. Rittenhouse-Olson’s training includes time as a post-doctoral fellow at Roswell Park Cancer Institute (RPCI), wherein she gained clinical tumor immunology experience with T. Ming Chu, (the discoverer of Prostate Specific Antigen for diagnosis) and then carbohydrate experience with Khushi Matta. For over 25 years her University of Buffalo (UB) laboratory has been involved in studying carbohydrate tumor associated antigens, and she has studied TF-Ag since 1985. Kate left her position as Professor and Director of the Biotechnology Program at the University of Buffalo to focus fully on bringing hJAA_F11 to the clinic.
Her role as the President of For-Robin is a natural fit since the JAA-F11 monoclonal antibody was developed in her UB laboratory and the company For-Robin is a start-up dedicated to efforts to bring JAA-F11 to the clinic. Most of the preclinical testing of this monoclonal antibody to the cancer target TF-Ag was performed under her direction. The protocols necessary for the testing of the humanized antibody to TF-Ag are in hand at UB and at For-Robin, Inc. Current techniques utilized in these laboratories include; molecular cloning , antibody production and purification, enzyme immunoassays, surface plasmon resonance, flow cytometry, immunotherapy and radioimmuno-localization in a mouse metastatic breast cancer model, ADCC, CDC assays, and assays for direct cytotoxicity.
Dr. Rittenhouse-Olson’s training as an immunologist, and her ASCP certification as a specialist in clinical immunology, along with her research experience amply suits the needs for her role as President of For-Robin. She supervises all aspects of the work, at UB and at For-Robin. She is committed to bringing the promising JAA-F11 antibody to clinical trials. Kate's is co-author of a clinical immunology textbook, Contemporary Clinical Immunology and Serology. She can be reached at krolson@For-Robin.com.
Chairman/Vice President University at Buffalo Distinguished Professor, with appointments in Pharmacology and Toxicology (School of Medicine and Biomedical Sciences) and Epidemiology and Environmental Health (School of Public Health and Health Professions), specializing in toxicology and the environmental health sciences. His research experience and expertise ranges from basic research on drug metabolism and disposition / pharmacokinetics to assessment of biomarkers of exposure, effect and susceptibility in large, international, population-based studies to better assess health risks in human populations. Dr. Olson has a 30+ year experience receiving extramural research funding from agencies including NIH, U.S. EPA, and CDC/ATSRD. His expertise helped to design the safety studies recently completed to bring JAA-F11 through the FDA IND stage. He can be reached at email@example.com.
Cheif Executive Officer Dr. Quataert has extensive experience and expertise in the development, validation and application of immunological methods for clinical translational research and vaccine evaluation. She has over 20 years experience in industry, with experience in regulatory compliance for GLP and GMP. Quataert has lead preclinical and clinical testing programs that provided the data supporting licensure of H.infuenzae b, Streptococcus pneumoniae, Neiserria meningiditis,live influenzae and subunit influenzae, rotavirus, and Pertussis subunit vaccines at Lederle-Praxis Biologics and Wyeth Vaccines. At the University of Rochester, she directed the Rochester Human Immunology Center Core laboratory and provides expertise and standardization for advanced immunological techniques including multichromatic flow cytometry, ELISPOT, ELISA, microbead-arrayed assays (Luminex) and blood processing across multiple programs requiring flu response evaluation. She is a registered quality assurance professional with certification in Good Laboratory Practices with experience in application to clinical and preclinical studies as well as cGMP production for vaccines. She can be reached at firstname.lastname@example.org